Due to the hemorrhagic risk, only 1.8–2.1% of U.S. ischemic stroke patients are treated with tPA per year with only an approximate annual 0.04–0.09% increase in this treatment number (Kleindorfer et al., 2008). This evidence concerns the gene PLAT and ischemic stroke.